Schein sews up Kruuse investment; Bayer launches first-in-class treatment for bovine lung disease; VetStem to tackle joint disease in horses;

> Distributor Henry Schein ($HSIC) has completed its 85 percent investment in Jorgen Kruuse, which distributes veterinary supplies in the Nordic countries. Release

> Bayer received authorization from the USDA to launch Zelnate, a first-in-class cytosine-phosphate-guanine (CpG) motif-based immunostimulant, which is being marketed to treat bovine respiratory disease. Release

> VetStem Biopharma announced it is launching a clinical research program centered around using stem cells to treat Equine Cervical Facet joint disease. Release

> The Journal of Dairy Science has published a study from Jaguar Animal Health ($JAGX) suggesting that its lead product, Neonorm, significantly relieved symptoms of E. coli diarrhea in neonatal calves. Release

> Dechra, a London-based specialty maker of veterinary pharmaceuticals, announced that its 2015 sales grew 10% year over year on a constant-currency basis to £203.5 million ($310.5 million) and its underlying operating profit jumped more than 11% to £44.4 million ($67.7 million). Release

> France's VitamFero has formed a licensing and distribution deal with Bioproperties of Australia to co-develop a toxoplasmosis vaccine for use in animals. Release

> MediVet Biologics has signed an agreement to work inside the Kansas Entrepreneurial Center testing a technology, developed by a Kansas State University professor, that uses donor stem cells to treat orthopedic problems in both animals and people. Article

> New Zealand-based Simcro has acquired the assets of ISL Animal Health and NJ Phillips to create a manufacturer of parasiticides, vaccines and antibiotics for use in production animals. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…